A5068667624- Cancer Immunotherapy and Biomarkers
- Head and Neck Cancer Studies
- Cancer Genomics and Diagnostics
- Cervical Cancer and HPV Research
- Immune cells in cancer
- Circadian rhythm and melatonin
- Dietary Effects on Health
- Immunotherapy and Immune Responses
- Lung Cancer Diagnosis and Treatment
- Biochemical and Molecular Research
- Radiomics and Machine Learning in Medical Imaging
- Pharmacogenetics and Drug Metabolism
- Diabetes Treatment and Management
- Ferroptosis and cancer prognosis
- Genomics and Rare Diseases
- Inflammatory mediators and NSAID effects
- Lung Cancer Research Studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
Massachusetts Eye and Ear Infirmary
2023-2025
Harvard University
2024-2025
Center for Cancer Research
2024-2025
Massachusetts General Hospital
2024-2025
Broad Institute
2024-2025
Massachusetts Institute of Technology
2024
Universidad del Rosario
2021-2022
Abstract Purpose While circulating tumor DNA (ctDNA) is a promising biomarker for minimal residual disease (MRD) detection in head and neck squamous cell carcinoma (HNSCC), more sensitive assays are needed accurate MRD at clinically-relevant timepoints. Ultrasensitive immediately after surgery could guide adjuvant therapy decisions, but early ctDNA dynamics poorly understood. Experimental Design We applied MAESTRO, whole-genome, tumor-informed, mutation-enrichment sequencing assay, pooled...
Immune checkpoint blockade (ICB) is the standard of care for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), yet efficacy remains low. The combined positive score (CPS) PD-L1 only biomarker approved to predict response ICB has limited performance. Tertiary Lymphoid Structures (TLS) have shown promising potential predicting ICB. However, their exact composition, size, spatial biology in HNSCC remain understudied. To elucidate impact TLS ICB, we utilized pre-ICB tumor...
In genes related to drug pharmacokinetics, molecular variations determine interindividual variability in the therapeutic efficacy and adverse reactions. The assessment of single-nucleotide variants (SNVs) is used with growing frequency pharmacogenetic practice, recently, high-throughput genomic analyses obtained through next-generation sequencing (NGS) have been recognized as powerful tools identify common, rare novel variants. These genetic profiles remain underexplored Latin-American...
Clopidogrel, an oral platelet P2Y12 receptor blocker, is used in the treatment of acute coronary syndrome. Interindividual variability response and occurrence adverse effects has been attributed to genetic variants CYP2C19. The analysis relevant pharmacogenes ethnically heterogeneous poorly studied populations contributes implementation personalized medicine. We analyzed coding regulatory regions CYP2C19 166 patients with syndrome (ACS) treated clopidogrel. allele frequencies alleles *1, *2,...
Abstract The adaptive immune response is physiologically regulated by the circadian rhythm. Data in lung and melanoma malignancies suggests immunotherapy infusions earlier day may be associated with improved response; however, optimal time of administration for patients HNSCC not known. We aimed to evaluate association infusion overall survival (OS) progression free (PFS) an Institutional Review Board-approved, retrospective cohort study. 113 met study inclusion criteria 98 were included a...
The potent immunostimulatory effects of toll-like receptor 8 (TLR8) agonism in combination with PD-1 blockade have resulted various preclinical investigations, yet the mechanism action humans remains unknown. To decipher combinatory mode TLR8 and blockade, we employed a unique, open-label, phase 1b pre-operative window opportunity clinical trial (NCT03906526) head neck squamous cell carcinoma (HNSCC) patients. Matched pre- post-treatment tumor biopsies from same lesion were obtained. We used...
The potent immunostimulatory effects of toll-like receptor 8 (TLR8) agonism in combination with PD-1 blockade have resulted various preclinical investigations, yet the mechanism action humans remains unknown. To decipher combinatory mode TLR8 and blockade, we employed a unique, open-label, phase 1b pre-operative window opportunity clinical trial (NCT03906526) head neck squamous cell carcinoma (HNSCC) patients. Matched pre- post-treatment tumor biopsies from same lesion were obtained. We used...
Immune checkpoint blockade (ICB) is the standard of care for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), yet efficacy remains low. The current approach predicting likelihood response to ICB a single proportional biomarker (PD-L1) expressed in immune tumor cells (Combined Positive Score, CPS) without differentiation by type, potentially explaining its limited predictive value. Tertiary Lymphoid Structures (TLS) have shown stronger association with than PD-L1. However,...
Abstract HPV-associated cancers, including oropharyngeal squamous cell carcinoma(HPV+OPSCC), cervical cancer(HPV+CC), and carcinoma of the anus(HPV+SCCA), release circulating tumor HPV DNA(ctHPVDNA) into blood. The diagnostic performance ctHPVDNA detection depends on approaches utilized individual assay metrics. A comparison these has not been systematically performed to inform expected performance, which in turn impacts clinical interpretation. meta-analysis was using Ovid MEDLINE, Embase,...